Article Type
Changed
Fri, 01/04/2019 - 11:11
Display Headline
David Henry's JCSO podcast, December 2015

In his December podcast for The Journal of Community and Supportive Oncology, Dr David Henry takes a look at filgrastim-sndz, the first biosimilar to be approved in United States. He also highlights two Original Reports that focus on cancer patients from racially diverse or underserved communities – one study looks at the patients’ enrollment in clinical trials; the other, at racial disparities in breast cancer diagnosis – as well as articles on the implementation of distress screening in an oncology setting and on oncology nurses’ perceptions of and practices and perceived barriers in regard to sexual health assessment and counseling among patients with cancer. The podcast rounds off with a discussion about a new era of combination therapy in cancer.

 

Publications
Legacy Keywords
Biosimilars, granulocytecolony stimulating factor, G-CSF, filgrastim-sndz, cancer, distress screening, quality of care, clinical trial enrollment, underserved patients, socioeconomic status, electronic medical record, EMR, urban safety net hospital, racial disparities, African American, breast cancer, mammography, sexual health, disease stage, oncology nurses, combination therapies, synergistic antitumor efficacy, pertuzumab, trastuzumab, ipilimumab, nivolumab, palbociclib, letrozole, lapatinib, docetaxel, trametinib, dabrafenib, carflzomib, lenalidomide
Sections

In his December podcast for The Journal of Community and Supportive Oncology, Dr David Henry takes a look at filgrastim-sndz, the first biosimilar to be approved in United States. He also highlights two Original Reports that focus on cancer patients from racially diverse or underserved communities – one study looks at the patients’ enrollment in clinical trials; the other, at racial disparities in breast cancer diagnosis – as well as articles on the implementation of distress screening in an oncology setting and on oncology nurses’ perceptions of and practices and perceived barriers in regard to sexual health assessment and counseling among patients with cancer. The podcast rounds off with a discussion about a new era of combination therapy in cancer.

 

In his December podcast for The Journal of Community and Supportive Oncology, Dr David Henry takes a look at filgrastim-sndz, the first biosimilar to be approved in United States. He also highlights two Original Reports that focus on cancer patients from racially diverse or underserved communities – one study looks at the patients’ enrollment in clinical trials; the other, at racial disparities in breast cancer diagnosis – as well as articles on the implementation of distress screening in an oncology setting and on oncology nurses’ perceptions of and practices and perceived barriers in regard to sexual health assessment and counseling among patients with cancer. The podcast rounds off with a discussion about a new era of combination therapy in cancer.

 

Publications
Publications
Article Type
Display Headline
David Henry's JCSO podcast, December 2015
Display Headline
David Henry's JCSO podcast, December 2015
Legacy Keywords
Biosimilars, granulocytecolony stimulating factor, G-CSF, filgrastim-sndz, cancer, distress screening, quality of care, clinical trial enrollment, underserved patients, socioeconomic status, electronic medical record, EMR, urban safety net hospital, racial disparities, African American, breast cancer, mammography, sexual health, disease stage, oncology nurses, combination therapies, synergistic antitumor efficacy, pertuzumab, trastuzumab, ipilimumab, nivolumab, palbociclib, letrozole, lapatinib, docetaxel, trametinib, dabrafenib, carflzomib, lenalidomide
Legacy Keywords
Biosimilars, granulocytecolony stimulating factor, G-CSF, filgrastim-sndz, cancer, distress screening, quality of care, clinical trial enrollment, underserved patients, socioeconomic status, electronic medical record, EMR, urban safety net hospital, racial disparities, African American, breast cancer, mammography, sexual health, disease stage, oncology nurses, combination therapies, synergistic antitumor efficacy, pertuzumab, trastuzumab, ipilimumab, nivolumab, palbociclib, letrozole, lapatinib, docetaxel, trametinib, dabrafenib, carflzomib, lenalidomide
Sections
Disallow All Ads
Alternative CME